218 related articles for article (PubMed ID: 28736931)
1. Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
Rotroff DM; Pijut SS; Marvel SW; Jack JR; Havener TM; Pujol A; Schluter A; Graf GA; Ginsberg HN; Shah HS; Gao H; Morieri ML; Doria A; Mychaleckyi JC; McLeod HL; Buse JB; Wagner MJ; Motsinger-Reif AA;
Clin Pharmacol Ther; 2018 Apr; 103(4):712-721. PubMed ID: 28736931
[TBL] [Abstract][Full Text] [Related]
2.
Morieri ML; Shah HS; Sjaarda J; Lenzini PA; Campbell H; Motsinger-Reif AA; Gao H; Lovato L; Prudente S; Pandolfi A; Pezzolesi MG; Sigal RJ; Paré G; Marcovina SM; Rotroff DM; Patorno E; Mercuri L; Trischitta V; Chew EY; Kraft P; Buse JB; Wagner MJ; Cresci S; Gerstein HC; Ginsberg HN; Mychaleckyj JC; Doria A
Diabetes; 2020 Apr; 69(4):771-783. PubMed ID: 31974142
[TBL] [Abstract][Full Text] [Related]
3. Summarizing the FIELD study: lessons from a 'negative' trial.
Tsimihodimos V; Mikhailidis DP; Elisaf M
Expert Opin Pharmacother; 2013 Dec; 14(18):2601-10. PubMed ID: 24206060
[TBL] [Abstract][Full Text] [Related]
4. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
5. [Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?].
Susekov AV; Khokhlova NV
Kardiologiia; 2011; 51(9):68-74. PubMed ID: 21943011
[No Abstract] [Full Text] [Related]
6. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
7. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
9. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Krysiak R; Okrzesik J; Szkrobka W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
[TBL] [Abstract][Full Text] [Related]
10. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway.
Al-Rasheed NM; Al-Rasheed NM; Al-Amin MA; Hasan IH; Al-Ajmi HN; Mohammad RA; Attia HA
Arch Physiol Biochem; 2016 Oct; 122(4):186-194. PubMed ID: 26959841
[TBL] [Abstract][Full Text] [Related]
12. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
14. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
[TBL] [Abstract][Full Text] [Related]
15. Significant association between rare IPO11-HTR1A variants and attention deficit hyperactivity disorder in Caucasians.
Zuo L; Saba L; Lin X; Tan Y; Wang K; Krystal JH; Tabakoff B; Luo X
Am J Med Genet B Neuropsychiatr Genet; 2015 Oct; 168(7):544-56. PubMed ID: 26079129
[TBL] [Abstract][Full Text] [Related]
16. The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Stulc T; Ceska R; Marinov I; Skrha J
Neuro Endocrinol Lett; 2012; 33 Suppl 2():73-7. PubMed ID: 23183514
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment.
Zhao S; Wang F; Dai Y; Lin L; Tong Q; Liao Y; Yin Y; Wang G; Yan Y; Li X; Wang D; Wei P; Cheng X; Xie Q; Sun Y; Fu G; Huang H; Dong Y; Liu J; Yan J; Yan L; Cui S; Liu X; Li Z; Chen H; Hu T; Gong H
Int J Cardiol; 2016 Oct; 221():832-6. PubMed ID: 27434354
[TBL] [Abstract][Full Text] [Related]
18. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Pruski M; Krysiak R; Okopien B
Diabetes Care; 2009 Aug; 32(8):1421-4. PubMed ID: 19435959
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
